bgb-dxp604
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04669262)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05381519 | Phase 2 | May 31, 2022 | Wuhan Institute of Biological Products Co., Ltd |
| NCT04669262 | Phase 1 | Dec 31, 2020 | BeOne Medicines |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 1 | 1 | 1 | 2020 |
| Wuhan Institute of Biological Products Co., Ltd | Government | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1